Advertisement

A Practitioner’s Guide to Prescribing Topiramate for Adults with Intellectual Disabilities

  • Jose de Leon
Chapter

Abstract

We developed this topiramate guideline using drug prescribing information and reviewing the available literature on relevant neuropsychiatric disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications, contraindications, assessments prior to and during treatment, dosing with particular focus on dosing modifications required by drug–drug interactions or personal characteristics, and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy in adult ­individuals with intellectual disabilities. A topiramate drug utilization review that summarizes this guideline is described.

Keywords

Eating Disorder Intellectual Disability Therapeutic Drug Monitoring Carbonic Anhydrase Inhibitor Slow Titration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abraham, G., & Owen, J. (2004). Topiramate can cause lithium toxicity. Journal of Clinical Psychopharmacology, 24, 565–567.PubMedCrossRefGoogle Scholar
  2. Adín, J., Gómez, M. C., Blanco, Y., Herranz, J. L., & Armijo, J. A. (2004). Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Therapeutic Drug Monitoring, 26, 251–257.PubMedCrossRefGoogle Scholar
  3. Anderson, G. D. (1998). A mechanistic approach to antiepileptic drug interactions. The Annals of Pharmacotherapy, 32, 554–563.PubMedCrossRefGoogle Scholar
  4. Arana, A., Wentworth, C. E., Ayuso-Mateos, J. L., & Arellano, F. M. (2010). Suicide-related events in patients treated with antiepileptic drugs. The New England Journal of Medicine, 363, 542–551.PubMedCrossRefGoogle Scholar
  5. Arbaizar, B., Gómez-Acebo, I., & Llorca, J. (2008). Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. General Hospital Psychiatry, 30, 471–475.PubMedCrossRefGoogle Scholar
  6. Arif, H., Buchsbaum, R., Weintraub, D., Pierro, J., Resor, S. R., Jr., & Hirsch, L. J. (2009). Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy and Behavior, 14, 202–209.PubMedCrossRefGoogle Scholar
  7. Arvio, M., & Sillanpää, M. (2005). Topiramate in long-term treatment of epilepsy in the intellectually disabled. Journal of Intellectual Disability Research, 49, 183–189.PubMedCrossRefGoogle Scholar
  8. Battino, D., Croci, D., Rossini, A., Messina, S., Mamoli, D., & Perucca, E. (2005). Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clinical Pharmacokinetics, 44, 407–416.PubMedCrossRefGoogle Scholar
  9. Bell, G. S., Mula, M., & Sander, J. W. (2009). Suicidality in people taking antiepileptic drugs: what is the evidence? CNS Drugs, 23, 281–292.PubMedCrossRefGoogle Scholar
  10. Benedetti, M. S. (2000). Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundamental and Clinical Pharmacology, 14, 301–319.PubMedCrossRefGoogle Scholar
  11. Ben-Menachem, E. (2007). Weight issues for people with epilepsy – a review. Epilepsia, 48(Suppl 9), 42–45.PubMedCrossRefGoogle Scholar
  12. Ben-Menachem, E., Axelsen, M., Johanson, E. H., Stagge, A., & Smith, U. (2003). Predictors of weight loss in adults with topiramate-treated epilepsy. Obesity Research, 11, 556–562.PubMedCrossRefGoogle Scholar
  13. Ben-Menachem, E., Sander, J. W., Stefan, H., Schwalen, S., & Schäuble, B. (2008). Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clinical Therapeutics, 30, 1180–1195.PubMedCrossRefGoogle Scholar
  14. Bialer, M., Doose, D. R., Murthy, B., Curtin, C., Wang, S. S., Twyman, R. E., et al. (2004). Pharmacokinetic interactions of topiramate. Clinical Pharmacokinetics, 43, 763–780.PubMedCrossRefGoogle Scholar
  15. Bjøro, K., Gjerstad, L., Bentdal, O., Osnes, S., & Schrumpf, E. (1998). Topiramate and fulminant liver failure. Lancet, 352, 1119.PubMedGoogle Scholar
  16. Britzi, M., Perucca, E., Soback, S., Levy, R. H., Fattore, C., Crema, F., et al. (2005). Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia, 46, 378–384.PubMedCrossRefGoogle Scholar
  17. Brodie, M. J. (2010). Antiepileptic drug therapy the story so far. Seizure, 19, 650–655.PubMedCrossRefGoogle Scholar
  18. Canitano, R. (2005). Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain and Development, 27, 228–232.PubMedCrossRefGoogle Scholar
  19. Carpay, J. A., Aalbers, K., Graveland, G. A., & Engelsman, M. (2009). Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy. Seizure, 18, 119–123.PubMedCrossRefGoogle Scholar
  20. Deutsch, S. I., Burket, J. A., & Rosse, R. B. (2009). Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clinical Neuropharmacology, 32, 350–352.PubMedCrossRefGoogle Scholar
  21. Doose, D. R., Brodie, M. J., Wilson, E. A., Chadwick, D., Oxbury, J., Berry, D. J., et al. (2003). Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia, 44, 917–922.PubMedCrossRefGoogle Scholar
  22. Doose, D. R., Walker, S. A., Gisclon, L. G., & Nayak, R. K. (1996). Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. Journal of Clinical Pharmacology, 36, 884–891.Google Scholar
  23. Doose, D. R., Wang, S. S., Padmanabhan, M., Schwabe, S., Jacobs, D., & Bialer, M. (2003). Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia, 44, 540–549.PubMedCrossRefGoogle Scholar
  24. Fontebasso, M. (2007). Topiramate for migraine prophylaxis. Expert Opinion on Pharmacotherapy, 8, 2811–2823.PubMedCrossRefGoogle Scholar
  25. FDA (2011) FDA drug safety communication: risk of oral clefts in children born to mothers taking Topamax (topiramate). http://www.fda.gov/Drugs/DrugSafety/ucm245085.htm. Accessed 11 April 2011.
  26. Fountoulakis, K. N., & Vieta, E. (2008). Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. The International Journal of Neuropsychopharmacology, 11, 999–1029.PubMedGoogle Scholar
  27. Genc, B. O., Dogan, E. A., Dogan, U., & Genc, E. (2010). Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment. Journal of Clinical Neuroscience, 17, 1256–1269.PubMedCrossRefGoogle Scholar
  28. Goyal, M., Grossberg, R. I., O’Riordan, M. A., & Davis, I. D. (2009). Urolithiasis with topiramate in nonambulatory children and young adults. Pediatric Neurology, 40, 289–294.PubMedCrossRefGoogle Scholar
  29. Guay, D. R. (2003). Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. The American Journal of Geriatric Pharmacotherapy, 1, 18–37.CrossRefGoogle Scholar
  30. Hachad, H., Ragueneau-Majlessi, I., & Levy, R. H. (2002). New antiepileptic drugs: review on drug interactions. Therapeutic Drug Monitoring, 24, 91–103.PubMedCrossRefGoogle Scholar
  31. Harden, C. L., & Leppik, I. (2006). Optimizing therapy of seizures in women who use oral contraceptives. Neurology, 67(Suppl 4), S56–S58.PubMedGoogle Scholar
  32. Harris, E. C., & Barraclough, B. (1997). Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry, 170, 205–228.PubMedCrossRefGoogle Scholar
  33. Herman, S. T. (2009). Adopting an orphan drug: rufinamide for Lennox–Gastaut syndrome. Epilepsy Current, 9, 72–74.CrossRefGoogle Scholar
  34. Hesdorffer, D. C., Berg, A. T., & Kanner, A. M. (2010). An update on antiepileptic drugs and suicide: are there definitive answers yet? Epilepsy Current, 10, 137–145.CrossRefGoogle Scholar
  35. Huber, B. (2002). Effects of topiramate in patients with epilepsy and intellectual deficits. Nervenarzt, 6, 525–532.CrossRefGoogle Scholar
  36. Jankovic, J., Jimenez-Shahed, J., & Brown, L. W. (2010). A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Journal of Neurology, Neurosurgery, and Psychiatry, 81, 70–73.PubMedCrossRefGoogle Scholar
  37. Janowsky, D. S., Kraus, J. E., Barnhill, J., Elamir, B., & Davis, J. M. (2003). Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviours in the intellectually disabled: an open-label retrospective study. Journal of Clinical Psychopharmacology, 23, 500–504.PubMedCrossRefGoogle Scholar
  38. Jette, N., Hemming, K., Hutton, J.L., Marson, A.G. (2008) Topiramate add-on for drug-resistant partial epilepsy. The Cochrane Database Systematic Reviews, 16, CD001417.Google Scholar
  39. Johannessen, S. I., & Tomson, T. (2006). Pharmacokinetic variability of newer antiepileptic drugs. When is monitoring needed? Clinical Pharmacokinetics, 45, 1061–1075.PubMedCrossRefGoogle Scholar
  40. Kalanin, V. V. (2007). Suicidality and antiepileptic drugs. Is there a link? Drug Safety, 30, 123–142.CrossRefGoogle Scholar
  41. Kanner, A. M. (2009). Can antiepileptic drugs unmask a susceptibility to psychiatric disorders? Nature Clinical Practice. Neurology, 5, 132–133.PubMedCrossRefGoogle Scholar
  42. Kaplon, D. M., Penniston, K. L., & Nakada, S. Y. (2011). Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate. Urology, 77, 295–298.PubMedCrossRefGoogle Scholar
  43. Kennedy, G. M., & Lhatoo, S. D. (2008). CNS adverse events associated with antiepileptic drugs. CNS Drugs, 22, 739–760.PubMedCrossRefGoogle Scholar
  44. Kerr, M. P., Baker, G. A., & Brodie, M. J. (2005). A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsy and Behavior, 7, 472–480.PubMedCrossRefGoogle Scholar
  45. Khanna, V., Arumugam, S., Roy, S., Mittra, S., & Bansal, V. S. (2008). Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opinion on Therapeutic Targets, 12, 81–90.PubMedCrossRefGoogle Scholar
  46. Knudsen, J. F., Sokol, G. H., & Flowers, C. M. (2008). Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. Journal of Clinical Pharmacy and Therapeutics, 33, 513–519.PubMedCrossRefGoogle Scholar
  47. Kossoff, E. H., Pyzik, P. L., Furth, S. L., Hladky, H. D., Freeman, J. M., & Vining, E. P. (2002). Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia, 43, 1168–1171.PubMedCrossRefGoogle Scholar
  48. Kuehn, B. M. (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. The Journal of the American Medical Association, 299, 1121–1122.PubMedCrossRefGoogle Scholar
  49. Lacy, C.F., Armstrong, L.L., Goldman, M.P., Lance, L.L. (2009) Drug information handbook, 18th edn. Hudson, OH: Lexi-Comp Inc.Google Scholar
  50. Latini, G., Verrotti, A., Manco, R., Scardapane, A., Del Vecchio, A., & Chiarelli, F. (2008). Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Reviews in Medicinal Chemistry, 8, 10–23.PubMedCrossRefGoogle Scholar
  51. Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., et al. (2005). Meta-analysis: pharmacologic treatment of obesity. Annals of Internal Medicine, 142, 532–546.PubMedGoogle Scholar
  52. Loring, D. W., Williamson, D. J., Meador, K. J., Wiegand, F., & Hulihan, J. (2011). Topiramate dose effects on cognition: a randomized double-blind study. Neurology, 76, 131–137.PubMedCrossRefGoogle Scholar
  53. Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., et al. (2007a). The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, 369, 1016–1026.CrossRefGoogle Scholar
  54. Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., et al. (2007b). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet, 369, 1000–1015.CrossRefGoogle Scholar
  55. Martin, P., Schreiner, A., Rettig, K., & Schäuble, B. (2009). Topiramate in patients with epilepsy and intellectual disability. Epilepsy and Behavior, 14, 496–502.PubMedCrossRefGoogle Scholar
  56. May, T. W., Rambeck, B., & Jürgens, U. (2002). Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Therapeutic Drug Monitoring, 24, 366–374.PubMedCrossRefGoogle Scholar
  57. McGeeney, B. E. (2003). Topiramate in the treatment of cluster headache. Current Pain and Headache Reports, 7, 135–158.PubMedCrossRefGoogle Scholar
  58. Merrick, J., Merrick, E., Lunsky, Y., & Kandel, I. (2006). A review of suicidality in persons with intellectual disability. The Israel Journal of Psychiatry and Related Sciences, 43, 258–264.PubMedGoogle Scholar
  59. Migliardi, G., D’Arrigo, C., Santoro, V., Bruno, A., Cortese, L., Campolo, M., et al. (2007). Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone and quetiapine in patients with psychotic disorders. Clinical Neuropharmacology, 30, 107–113.PubMedCrossRefGoogle Scholar
  60. Mimrod, D., Specchio, L. M., Britzi, M., Perucca, E., Specchio, N., La Neve, A., et al. (2005). A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia, 46, 1046–1054.PubMedCrossRefGoogle Scholar
  61. Mula, M., & Sander, J. W. (2007). Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Safety, 30, 555–567.PubMedCrossRefGoogle Scholar
  62. Mirza, N., Marson, A. G., & Pirmohamed, M. (2009). Effect of topiramate on acid–base balance: extent, mechanism and effects. British Journal of Clinical Pharmacology, 68, 655–661.PubMedCrossRefGoogle Scholar
  63. Mula, M., Hesdorffer, D. C., Trimble, M., & Sander, J. W. (2009). The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia, 50, 1072–1076.PubMedCrossRefGoogle Scholar
  64. Mula, M., Pini, S., & Cassano, G. B. (2007). The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. Journal of Clinical Psychopharmacology, 27, 263–272.PubMedCrossRefGoogle Scholar
  65. Nallani, S. C., Glauser, T. A., Hariparsad, N., Setchell, K., Buckley, D. J., Buckley, A. R., et al. (2003). Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia, 44, 1521–1528.PubMedCrossRefGoogle Scholar
  66. Ohman, I., Vitols, S., Luef, G., Söderfeldt, B., & Tomson, T. (2002). Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia, 43, 1157–1160.PubMedCrossRefGoogle Scholar
  67. Ohman, I., Sabers, A., de Flon, P., Luef, G., & Tomson, T. (2009). Pharmacokinetics of topiramate during pregnancy. Epilepsy Research, 87, 124–129.PubMedCrossRefGoogle Scholar
  68. Olmsted, C. L., & Kockler, D. R. (2008). Topiramate for alcohol dependence. The Annals of Pharmacotherapy, 42, 1475–1480.PubMedCrossRefGoogle Scholar
  69. Ortho-McNeil-Janssen Pharmaceuticals (2011) Topamax (topiramate) tablets for oral use. Topamax (topiramate capsules) sprinkle capsules for oral use (highlights of prescribing information). Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals.Google Scholar
  70. Patsalos, P. N. (2004). Clinical pharmacokinetics of levetiracetam. Clinical Pharmacokinetics, 43, 707–724.PubMedCrossRefGoogle Scholar
  71. Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., et al. (2008). Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring ILAE Commission on Therapeutic Strategies. Epilepsia, 49, 1239–1276.PubMedCrossRefGoogle Scholar
  72. Perucca, E. (2006). Clinically relevant drug interactions with antiepileptic drugs. British Journal of Clinical Pharmacology, 61, 246–255.PubMedCrossRefGoogle Scholar
  73. Pinninti, N. R., & Zelinski, G. (2002). Does topiramate elevate serum lithium levels? (letter) Journal of Clinical Psychopharmacology, 22, 340.PubMedCrossRefGoogle Scholar
  74. Ramsay, R. E., Uthman, B., Pryor, F. M., Rowan, A. J., Bainbridge, J., Spitz, M., et al. (2008). Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia, 49, 1180–1185.PubMedCrossRefGoogle Scholar
  75. Reimers, A., Skogvoll, E., Sund, J. K., & Spigset, O. (2005). Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. Journal of Clinical Psychopharmacology, 25, 342–348.PubMedCrossRefGoogle Scholar
  76. Rezaei, V., Mohammadi, M. R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S. A., et al. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 1269–1272.PubMedCrossRefGoogle Scholar
  77. Rogwaski, M. A., & Löscher, W. (2004). The neurobiology of antiepileptic drugs. Nature Reviews. Neuroscience, 5, 553–564.CrossRefGoogle Scholar
  78. Rosenfeld, W. E., Doose, D. R., Walker, S. A., & Nayak, R. K. (1997). Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia, 38, 317–323.PubMedCrossRefGoogle Scholar
  79. Rosenfeld, W. E., Liao, S., Kramer, L. D., Anderson, G., Palmer, M., Levy, R. H., et al. (1997). Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia, 38, 324–333.PubMedCrossRefGoogle Scholar
  80. Sachdeo, R. C., Sachdeo, S. K., Levy, R. H., Streeter, A. J., Bishop, F. E., Kunze, K. L., et al. (2002). Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia, 43, 691–696.PubMedCrossRefGoogle Scholar
  81. Sachdeo, R. C., Sachdeo, S. K., Walker, S. A., Kramer, L. D., Nayak, R. K., & Doose, D. R. (1996). Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia, 3, 774–780.CrossRefGoogle Scholar
  82. Saneto, R. P., & Anderson, G. D. (2009). Onset of action and seizure control in Lennox–Gastaut syndrome: focus on rufinamide. Therapeutics and Clinical Risk Management, 5, 271–280.PubMedCrossRefGoogle Scholar
  83. Schneiderman, J. H. (1998). Topiramate: pharmacokinetics and pharmacodynamics. The Canadian Journal of Neurological Sciences, 25, S3–S5.PubMedGoogle Scholar
  84. Shank, R. P., & Maryanoff, B. E. (2008). Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neuroscience and Therapeutics, 14, 120–142.PubMedCrossRefGoogle Scholar
  85. Shapira, N. A., Lessig, M. C., Lewis, M. H., Goodman, W. K., & Driscoll, D. J. (2004). Effects of topiramate in adults with Prader–Willi syndrome. American Journal of Mental Retardation, 109, 301–309.PubMedCrossRefGoogle Scholar
  86. Sills, G., & Brodie, M. (2007). Pharmacokinetics and drug interactions with zonisamide. Epilepsia, 48, 435–441.PubMedCrossRefGoogle Scholar
  87. Simister, R. J., Sander, J. W., & Koepp, M. J. (2007). Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy and Behavior, 2, 336–339.CrossRefGoogle Scholar
  88. Singh, B. K., & White-Scott, S. (2002). Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure, 11, 47–50.PubMedCrossRefGoogle Scholar
  89. Sirven, J. I., Fife, T. D., Wingerchuk, D. M., & Drazkowski, J. F. (2007). Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clinic Proceedings, 82, 40–47.PubMedGoogle Scholar
  90. Smathers, S. A., Wilson, J. G., & Nigro, M. A. (2003). Topiramate effectiveness in Prader–Willi syndrome. Pediatric Neurology, 28, 130–133.PubMedCrossRefGoogle Scholar
  91. Stafstrom, C. E. (2009). Update on the management of Lennox–Gastaut syndrome with a focus on rufinamide. Neuropsychiatric Disease and Treatment, 5, 547–551.PubMedCrossRefGoogle Scholar
  92. Supuran, C. T., Di Fiore, A., & De Simone, G. (2008). Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opinion on Emerging Drugs, 13, 383–392.PubMedCrossRefGoogle Scholar
  93. US Department of Mental Health and Human Services (2008) Statistical review and evaluation: antiepileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed 5 April 2011.
  94. van Passel, L., Arif, H., & Hirsch, L. J. (2006). Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Review of Neurotherapeutics, 6, 19–31.PubMedCrossRefGoogle Scholar
  95. Vasudev, K., Macritchie, K., Geddes, J., Watson, S., Young, A. (2006) Topiramate for acute affective episodes in bipolar disorder. The Cochrane Database Systematic Reviews, CD003384.Google Scholar
  96. Vohora, D., Saraogi, P., Yazdani, M. A., Bhowmik, M., Khanam, R., & Pillai, K. K. (2010). Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-­generation antiepileptic drugs. Drugs of Today (Barcelona, Spain), 46, 265–277.CrossRefGoogle Scholar
  97. Vovk, T., Jakovljević, M. B., Kos, M. K., Janković, S. M., Mrhar, A., & Grabnar, I. (2010). A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. Biological and Pharmaceutical Bulletin, 33, 1176–1182.PubMedCrossRefGoogle Scholar
  98. Westin, A. A., Nakken, K. O., Johannessen, S. I., Reimers, A., Lillestølen, K. M., & Brodtkorb, E. (2009). Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia, 50, 480–485.PubMedCrossRefGoogle Scholar
  99. Wong, I. C., & Lhatoo, S. D. (2000). Adverse reactions to new anticonvulsant drugs. Drug Safety, 23, 35–56.PubMedCrossRefGoogle Scholar
  100. Working Group of the International Association of the Scientific Study of Intellectual Disability. (2001). Clinical guidelines for the management of epilepsy in adults with an intellectual disability. Seizure, 10, 401–409.CrossRefGoogle Scholar
  101. Wroe, S. (2007). Zonisamide and renal calculi in patients with epilepsy: how big an issue? Current Medical Research and Opinion, 23, 1765–1773.PubMedCrossRefGoogle Scholar
  102. Zaccara, G., Gangemi, P. F., & Cincotta, M. (2008). Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure, 17, 405–421.PubMedCrossRefGoogle Scholar
  103. Zaccara, G., Messori, A., Cincotta, M., & Burchini, G. (2006). Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurologica Scandinavica, 114, 157–168.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jose de Leon
    • 1
  1. 1.Department of Psychiatry College of MedicineUniversity of KentuckyLexingtonUSA

Personalised recommendations